

Grand Rounds

Friday, May 17, 9:00am

Dissecting and Overcoming Different Shades of Cancer Immune Evasion

featuring

Benjamin Izar, MD, PhD

**Vivian and Seymour Milstein Family Assistant
Professor of Medicine, Columbia Vagelos
College of Physicians and Surgeons**

55 Park Street Auditorium | Zoom Access


Continental breakfast will be available

Needs: Clinicians treating patients with advanced cancers that may lead to brain metastasis. Clinicians treating patients with cancers requiring immunotherapies. Basic scientists interrogating mechanisms of cancer immune evasion. Basic scientists interrogating mechanisms of genomic instability.

Objectives: Understand mechanisms of cancer immune evasion in melanoma. Mechanisms of metastatic organotropism to the brain and potential clinical implications. Methods for improving cell therapies.



There is No Corporate Support for These Activities. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement: The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Target Audience: YCC members, Smilow faculty, YSM, Nursing, Public Health Students. Faculty Disclosures: Winer- nothing to disclose. Izar-Consulting Fee-Janssen | Consulting Fee-Novartis | Consulting Fee-AstraZeneca | Consulting Fee-Merck | Consulting Fee-Synthekine | Consulting Fee-Eisai. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. Mitigation of Financial Relationships Statement: Yale CME adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.



Dr. Izar's clinical practice focuses on melanoma and cancer immunotherapy. In his lab, he studies interactions between cancer cells and cells of the tumor-microenvironment, and how these define metastatic niches and response and resistance to cancer immunotherapies.

Dr. Izar received his MD/PhD at Justus Liebig University in Giessen, Germany. He completed his residency training at Massachusetts General Hospital and medical oncology training at Beth Israel Deaconess Medical Center, followed by his first faculty position at Dana-Farber Cancer Institute. He completed post-doctoral research training in cancer immunology at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard. In addition to several awards he received during his training, Dr. Izar is the recipient of multiple national awards.